Abbott Laboratories $ABT Shares Sold by Gibbs Wealth Management

Gibbs Wealth Management lessened its stake in Abbott Laboratories (NYSE:ABT) by 53.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 15,626 shares of the healthcare product maker’s stock after selling 18,022 shares during the quarter. Gibbs Wealth Management’s holdings in Abbott Laboratories were worth $2,093,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares in the last quarter. Signet Financial Management LLC lifted its stake in Abbott Laboratories by 6.5% during the second quarter. Signet Financial Management LLC now owns 3,066 shares of the healthcare product maker’s stock worth $417,000 after purchasing an additional 188 shares during the last quarter. McAdam LLC increased its stake in Abbott Laboratories by 15.7% in the second quarter. McAdam LLC now owns 2,780 shares of the healthcare product maker’s stock valued at $378,000 after purchasing an additional 377 shares during the last quarter. Finally, Register Financial Advisors LLC raised its holdings in Abbott Laboratories by 49.5% during the second quarter. Register Financial Advisors LLC now owns 3,590 shares of the healthcare product maker’s stock worth $488,000 after purchasing an additional 1,188 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: MedTech and pharma strength, and EPS resilience — Abbott reported adjusted Q4 EPS growth (company highlighted margin improvements) and strong MedTech (+~12%) and Established Pharma (+~9%) performance that partly offset Nutrition weakness; management still projects FY?2026 adjusted EPS growth. Press Release
• Positive Sentiment: Analysts keep buy/outperform stance despite cuts — several major firms trimmed price targets after the print but largely maintained buy/overweight ratings, signaling conviction in the longer?term story even as near?term expectations were tempered. Analyst Reaction
• Positive Sentiment: Some commentators view the pullback as a buying opportunity — market commentators highlight ABT’s dividend history, cash flow and buyback capacity, suggesting the drop may create an attractive entry for long?term investors. MarketBeat: Pullback Analysis
• Neutral Sentiment: Full earnings call and transcripts available — investors can review management commentary and segment detail in the Q4 earnings call transcript for color on nutrition, diagnostics and Exact/other strategic items. Earnings Transcript
• Neutral Sentiment: Dividend/valuation commentary circulates — value and dividend?focused outlets are flagging ABT as attractively valued after the pullback; this is background context rather than a near?term catalyst. Zacks: Value Take
• Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics — Q4 revenue (~$11.5B) fell short of consensus, with Nutrition down sharply (~8–9%) and Diagnostics weak, sparking the initial selloff. Reuters: Revenue Miss
• Negative Sentiment: Guidance slightly below Street — Abbott set Q1 EPS and FY?2026 EPS ranges that sit near or a touch below consensus, increasing near?term revenue/growth concerns. Guidance Details
• Negative Sentiment: Multiple price?target cuts — a raft of firms (Citigroup, Goldman, Raymond James, Sanford Bernstein, Oppenheimer, RBC, etc.) trimmed targets, which can amplify selling pressure even if ratings remain constructive. Benzinga: PT Cuts
• Negative Sentiment: Options and hedging activity spiked — an unusual surge in put buying suggests traders are positioning for further near?term downside (heightened bearish sentiment).
• Negative Sentiment: Regulatory scrutiny in India — reports of an investigation into alleged misuse of a codeine?based cough syrup (Abbott Healthcare) add an extra headline risk in emerging markets. Reuters: India Scrutiny

Analyst Ratings Changes

Several brokerages recently commented on ABT. Piper Sandler cut their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday. Evercore ISI cut their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday. Sanford C. Bernstein decreased their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday. Wells Fargo & Company lifted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Finally, Citigroup decreased their price objective on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $140.79.

Abbott Laboratories Stock Down 1.1%

Abbott Laboratories stock opened at $107.46 on Friday. The stock has a market capitalization of $186.86 billion, a price-to-earnings ratio of 28.89, a PEG ratio of 1.80 and a beta of 0.72. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The stock has a 50 day moving average of $124.77 and a two-hundred day moving average of $128.36. Abbott Laboratories has a twelve month low of $105.78 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a dividend of $0.63 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.